Physician profile
Luis J Bird
NPI 1538222658
$10,758.03
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,449 · 2020: $825 · 2021: $2,035 · 2022: $2,096 · 2023: $1,921 · 2024: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,341 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,340.66 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,551.57 | 2019-2024 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $1,514.45 | 2019-2024 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $1,472.78 | 2019-2024 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Abbvie INC. | $913.07 | 2021-2024 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $856.10 | 2019-2024 | Austedo Xr, Austedo, Uzedy |
| Neurocrine Biosciences, INC. | $798.61 | 2019-2024 | Ingrezza |
| Lundbeck LLC | $754.53 | 2019-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $676.92 | 2019-2024 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $547.97 | 2020-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $490.24 | 2019-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $465.75 | 2019-2022 | |
| Indivior INC. | $344.56 | 2019-2024 | Perseris |
| Allergan, INC. | $82.45 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $67.44 | 2019-2022 | |
| Noven Therapeutics, LLC | $66.69 | 2020-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $43.53 | 2024 | |
| Braeburn INC. | $29.87 | 2024 | Brixadi |
| Neuronetics, INC. | $23.42 | 2023 | Neurostar Tms Therapy System |
| Axsome Therapeutics, INC. | $22.55 | 2023 | Auvelity |
| Idorsia Pharmaceuticals US INC | $20.42 | 2023 | Quviviq |
| Almatica Pharma LLC | $15.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Bird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.